The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer

• 成果类型: Article
• 署名作者: Abraham, Jean E.; Pinilla, Karen; Dayimu, Alimu; Grybowicz, Louise; Demiris, Nikolaos; Harvey, Caron; Drewett, Lynsey M.; Lucey, Rebecca; Fulton, Alexander; Roberts, Anne N.; Worley, Joanna R.; Chhabra, Anita; Qian, Wendi; Vallier, Anne-Laure; Hardy, Richard M.; Chan, Steve; Hickish, Tamas; Tripathi, Devashish; Venkitaraman, Ramachandran; Persic, Mojca; Aslam, Shahzeena; Glassman, Daniel; Raj, Sanjay; Borley, Annabel; Braybrooke, Jeremy P.; Sutherland, Stephanie; Staples, Emma; Scott, Lucy C.; Davies, Mark; Palmer, Cheryl A.; Moody, Margaret; Churn, Mark J.; Newby, Jacqueline C.; Mukesh, Mukesh B.; Chakrabarti, Amitabha; Roylance, Rebecca R.; Schouten, Philip C.; Levitt, Nicola C.; Mcadam, Karen; Armstrong, Anne C.; Copson, Ellen R.; Mcmurtry, Emma; Tischkowitz, Marc; Provenzano, Elena; Earl, Helena M.
• 署名单位: University of Cambridge; Cancer Research UK; University of Cambridge; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; Athens University of Economics & Business; University of Cambridge; University of Cambridge; Nottingham University Hospital NHS Trust; University of Nottingham; Russells Hall Hospital; Ipswich Hospital NHS Trust; Pinderfields Hospital; University of Southampton; University Hospital Southampton NHS Foundation Trust; Velindre Cancer Centre; Mount Vernon Cancer Centre; Beatson Oncology Centre; University of London; University College London; Royal Free London NHS Foundation Trust; University of London; University College London; University College London Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Oxford University Hospitals NHS Foundation Trust; University of Manchester; Christie NHS Foundation Trust; University of Southampton; University of Cambridge
• 刊物名称: Nature
• ISSN/ISSBN: 0028-5824
• DOI: 10.1038/s41586-024-07384-2
• 发表日期: 2024-05-30
• 关键词: adjuvant capecitabine; mutations

摘要

PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer(1,2), who were germline BRCA1 and BRCA2 wild type(3). Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)(4), and secondary end points included event-free survival (EFS) and overall survival (OS)(5). pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin-paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type.